What is Neophore?
Established in 2017, Neophore operates at the intersection of immunology and oncology. The company is dedicated to the development of small molecule therapies designed to enhance the body's natural immune response against cancer cells. By focusing on innovative therapeutic targets, Neophore aims to address significant unmet clinical needs in the oncology sector. The firm's strategic positioning within the United Kingdom's vibrant biotech ecosystem allows it to collaborate with leading research institutions and leverage deep scientific expertise to bring transformative treatments to market.
How much funding has Neophore raised?
Neophore has raised a total of $45.5M across 3 funding rounds:
Private Equity
$3.8M
Other Financing Round
$2.1M
Series B
$39.5M
Private Equity (2017): $3.8M with participation from Sixth Element Capital LLP
Other Financing Round (2017): $2.1M led by Sixth Element Capital LLP
Series B (2024): $39.5M supported by 3B Future Health Fund, Astellas Venture Management, Sixth Element Capital, and Claris Ventures
Key Investors in Neophore
3B Future Health Fund
A specialized fund focusing on early-stage healthcare innovation, particularly in oncology and rare diseases, with a commitment to supporting first-in-class treatments.
Astellas Venture Management
The corporate venture arm of Astellas Pharma, dedicated to reinforcing the parent company's strategic interests through targeted investments in innovative life sciences startups.
Sixth Element Capital
A UK-based fund manager that bridges the investment gap between cancer drug discovery and early development, focusing on bringing novel therapeutic products to market.
What's next for Neophore?
With the successful closure of its latest financing round, Neophore is poised to enter a critical phase of growth. The strategic allocation of these funds will likely prioritize the advancement of its lead candidates through preclinical and early clinical development stages. As the company matures, the focus will shift toward validating its therapeutic platform and establishing potential partnerships with larger pharmaceutical entities to facilitate late-stage trials and commercialization. This trajectory highlights Neophore's commitment to long-term value creation in the biopharmaceutical industry, as it continues to refine its pipeline of novel cancer-fighting agents.
See full Neophore company page
